Pneumococcal

Researchers explore community-acquired pneumococcal-related hospital admissions among adults from 2000 to 2019 and assess pneumococcal immunization’s impact after the year 2015.

Researchers investigate serotype distribution and antimicrobial resistance among children in Mexico with pneumococcal meningitis.

Researchers conduct a cost-effectiveness analysis to uncover the public health and economic impacts of PCV20 among Australian children.

After nearly 20 years of pneumococcal conjugate vaccine use in the Portuguese vaccine schedule, researchers explore serotype distribution in bacteria causing adult invasive pneumococcal disease (IPD).

With disease cases increasing substantially between 2012 and 2024, higher-valent vaccines are necessary to protect against nonvaccine serotypes and invasive pneumococcal disease.

Study findings highlight the need for further exploration into the racial and ethnic trends of pneumococcal vaccination rates.

To optimize vaccine strategies among young people with Down syndrome, researchers explore the prevalence of adequate immune responses following pneumococcal vaccination.

Pneumococcal conjugate vaccines significantly reduce pneumonia incidence in children, but safety concerns warrant further investigation in future studies.

PCV21 improved all outcomes for individuals aged 19 to 64 years, including invasive pneumococcal disease, postmeningitis sequelae, and nonbacteremic pneumococcal pneumonia.

At the NCPA 2025 Annual Convention & Expo, Jeannie Grubbs, PharmD, manager at Publix Pharmacy, presented on the reasons why pneumococcal vaccine development is an ongoing process.

Researchers investigate which pneumococcal strains were most responsible for invasive infections among children in Poland.

With emerging vaccines causing a decrease in community-acquired bacterial meningitis, researchers investigated how the prominence in disease pathogens has evolved over 15 years in Korea.

With uncertainty in dosing recommendations, researchers aim to assess the efficacy of pneumococcal conjugate vaccines for the pediatric population.

Significant patient reports show a lack of response to treatment for community-acquired pneumonia, leading researchers to investigate the use of corticosteroids.

The study results highlight the importance of pneumococcal vaccination for patients with chronic respiratory diseases, particularly chronic obstructive pulmonary disease.

Further, after the introduction of the pneumococcal conjugate vaccine 10, investigators note a decrease of infections caused by multidrug resistance infection.

Using the Vaccine Adverse Event Reporting System database, researchers address adverse events following pneumococcal vaccination, as well as the association between adverse events and vaccine administration.

Merck’s pneumococcal 21-valent conjugate vaccine was noninferior to the pneumococcal 23-valent polysaccharide vaccine for all 12 shared serotypes and superior to 9 unique serotypes.

Due to an increased risk of vaccine-preventable diseases, researchers explore pneumococcal, COVID-19, and influenza vaccine coverage among people living with HIV in Belgium.

Exploring the influences of pneumococcal disease mortality and events of the COVID-19 pandemic, researchers investigate changes in US pneumococcus survival rates since 2020.

Researchers explored the impact of PCV10 on the distribution of invasive pneumococcal disease serotypes among patients in Lithuania.

Simultaneous vaccination with IIV4 and PPSV23 proves safe and effective for patients with chronic diseases, matching results of healthy individuals.

Investigators find a large burden of hospitalization due to community-acquired pneumonia (CAP) for adults in the US, mainly caused by Streptococcus pneumoniae.

Among rural community pharmacies in the US, researchers explored pneumococcal immunization services, the processes used to identify patient eligibility, and the barriers to vaccine administration.